1. A look at current and potential treatment approaches for hormone receptor‐positive, HER2‐negative early breast cancer. (10th May 2022) Authors: Harbeck, Nadia; Burstein, Harold J.; Hurvitz, Sara A.; Johnston, Stephen; Vidal, Gregory A. Journal: Cancer Issue: Volume 128:Supplement S11(2022) Page Start: 2209 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation: EMBRACA subgroups by age. (October 2018) Authors: Yerushalmi, Rinat; Eiermann, Wolfgang; Rugo, Hope; Ettl, Johannes; Hurvitz, Sara A.; Gonçalves, Anthony; Miguel, Martin; Markova, Denka; Tudor, Iulia; Blum, Joanne; Hannah, Alison; Litton, Jennifer Journal: Breast Issue: Volume 41(2018)Supplement 1 Page Start: S12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential. (September 2014) Authors: Peddi, Parvin F.; Hurvitz, Sara A. Journal: Therapeutic advances in medical oncology Issue: Volume 6:Number 5(2014:Sep.) Page Start: 202 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer. (March 2022) Authors: Bardia, Aditya; Cortes, Javier; Hurvitz, Sara A.; Delaloge, Suzette; Iwata, Hiroji; Shao, Zhi-Ming; Kanagavel, Dheepak; Cohen, Patrick; Liu, Qianying; Cartot-Cotton, Sylvaine; Pelekanou, Vasiliki; O'Shaughnessy, Joyce Journal: Therapeutic advances in medical oncology Issue: Volume 14(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Antibody–drug conjugates: an emerging modality for the treatment of cancer. (August 2014) Authors: Leal, Mauricio; Sapra, Puja; Hurvitz, Sara A.; Senter, Peter; Wahl, Alan; Schutten, Melissa; Shah, Dhaval K.; Haddish‐Berhane, Nahor; Kabbarah, Omar Journal: Annals of the New York Academy of Sciences Issue: Volume 1321(2014) Page Start: 41 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Chemotherapy regimen choice and patient outcomes in early-stage triple-negative breast cancer: a retrospective analysis. (April 2022) Authors: Ghafouri, Sanaz N.; Nayeri, Rebecca W.; McAndrew, Nicholas P.; Hurvitz, Sara A. Journal: Therapeutic advances in medical oncology Issue: Volume 14(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry. (14th October 2019) Authors: Tripathy, Debu; Brufsky, Adam; Cobleigh, Melody; Jahanzeb, Mohammad; Kaufman, Peter A.; Mason, Ginny; O'Shaughnessy, Joyce; Rugo, Hope S.; Swain, Sandra M.; Yardley, Denise A.; Chu, Laura; Li, Haocheng; Antao, Vincent; Hurvitz, Sara A. Journal: Oncologist Issue: Volume 25:Number 2(2020) Page Start: e214 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Do all patients with cancer experience fatigue? A longitudinal study of fatigue trajectories in women with breast cancer. Issue 8 (19th February 2021) Authors: Bower, Julienne E.; Ganz, Patricia A.; Irwin, Michael R.; Cole, Steve W.; Garet, Deborah; Petersen, Laura; Asher, Arash; Hurvitz, Sara A.; Crespi, Catherine M. Journal: Cancer Issue: Volume 127:Issue 8(2021) Page Start: 1334 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial. (7th June 2021) Authors: Hurvitz, Sara A.; Saura, Cristina; Oliveira, Mafalda; Trudeau, Maureen E.; Moy, Beverly; Delaloge, Suzette; Gradishar, William; Kim, Sung-Bae; Haley, Barbara; Ryvo, Larisa; Dai, Ming-Shen; Milovanov, Vladimir; Alarcón, Jesús; Kalmadi, Sujith; Cronemberger, Eduardo; Souza, Cristiano; Landeiro, Luc... Journal: Oncologist Issue: Volume 26:Number 8(2021) Page Start: e1327 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial. (7th June 2021) Authors: Hurvitz, Sara A.; Saura, Cristina; Oliveira, Mafalda; Trudeau, Maureen E.; Moy, Beverly; Delaloge, Suzette; Gradishar, William; Kim, Sung‐Bae; Haley, Barbara; Ryvo, Larisa; Dai, Ming‐Shen; Milovanov, Vladimir; Alarcón, Jesús; Kalmadi, Sujith; Cronemberger, Eduardo; Souza, Cristiano; Landeiro, Luc... Journal: Oncologist Issue: Volume 26:Number 8(2021) Page Start: e1327 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗